Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Stock Slides 9 Percent on Widened Q4 Loss

NEW YORK, Feb. 25 (GenomeWeb News) - Shares in CombiMatrix were down more than 9 percent, or $.30, at $3 in mid-afternoon trading after the company reported a significant increase in net loss for the fourth quarter.

 

As GenomeWeb News reported this morning, CombiMatrix yesterday said that net losses for the three-month period Dec. 31, 2004, surged 44 percent to $1.6 million from $1.1 million in the year-ago period.

 

The Mulkiteo, Wash.-based company also said revenues for the quarter jumped to $522,000 from $53,000 for the same quarter last year.

 

CombiMatrix said it spent $1.4 million on R&D in the quarter, down 27 percent from $1.9 million in the fourth quarter of 2003.

 

CombiMatrix said it had around $23.7 million in cash, equivalents, and short-term investments as of Dec. 31, 2004.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.